Phentermine Hydrochloride Market Size to Hit USD 1,115.57 Mn by 2034

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. Market Dynamics Analysis and Trends

5.1. Market Dynamics

5.1.1. Market Drivers

5.1.2. Market Restraints

5.1.3. Market Opportunities

5.2. Porter’s Five Forces Analysis

5.2.1. Bargaining power of suppliers

5.2.2. Bargaining power of buyers

5.2.3. Threat of substitute

5.2.4. Threat of new entrants

5.2.5. Degree of competition

Chapter 6. Competitive Landscape

6.1.1. Company Market Share/Positioning Analysis

6.1.2. Key Strategies Adopted by Players

6.1.3. Vendor Landscape

6.1.3.1. List of Suppliers

6.1.3.2. List of Buyers

Chapter 7. Global Phentermine Hydrochloride Market, By Dosage Form

7.1. Phentermine Hydrochloride Market Revenue and Volume, by Dosage Form

7.1.1. Tablets

7.1.1.1. Market Revenue and Volume Forecast

7.1.2. Capsules

7.1.2.1. Market Revenue and Volume Forecast

7.1.3. Orally Disintegrating Tablets (ODT)

7.1.3.1. Market Revenue and Volume Forecast

7.1.4. Extended-Release Formulations

7.1.4.1. Market Revenue and Volume Forecast

Chapter 8. Global Phentermine Hydrochloride Market, By Strength

8.1. Phentermine Hydrochloride Market Revenue and Volume, by Strength

8.1.1. 8 mg

8.1.1.1. Market Revenue and Volume Forecast

8.1.2. 15 mg

8.1.2.1. Market Revenue and Volume Forecast

8.1.3. 18.75 mg

8.1.3.1. Market Revenue and Volume Forecast

8.1.4. 30 mg

8.1.4.1. Market Revenue and Volume Forecast

8.1.5. 37.5 mg

8.1.5.1. Market Revenue and Volume Forecast

Chapter 9. Global Phentermine Hydrochloride Market, By Route of Administration

9.1. Phentermine Hydrochloride Market Revenue and Volume, by Route of Administration

9.1.1. Oral

9.1.1.1. Market Revenue and Volume Forecast

9.1.2. Sublingual

9.1.2.1. Market Revenue and Volume Forecast

Chapter 10. Global Phentermine Hydrochloride Market, By Distribution Channel

10.1. Phentermine Hydrochloride Market Revenue and Volume, by Distribution Channel

10.1.1. Hospital Pharmacies

10.1.1.1. Market Revenue and Volume Forecast

10.1.2. Retail Pharmacies

10.1.2.1. Market Revenue and Volume Forecast

10.1.3. Online Pharmacies

10.1.3.1. Market Revenue and Volume Forecast

10.1.4. Weight Loss Clinics

10.1.4.1. Market Revenue and Volume Forecast

Chapter 11. Global Phentermine Hydrochloride Market, By Application

11.1. Phentermine Hydrochloride Market Revenue and Volume, by Application

11.1.1. Obesity (BMI ≥30)

11.1.1.1. Market Revenue and Volume Forecast

11.1.2. Overweight with Comorbidities (BMI ≥27 with conditions like hypertension, diabetes)

11.1.2.1. Market Revenue and Volume Forecast

Chapter 12. Global Phentermine Hydrochloride Market, By End User

12.1. Phentermine Hydrochloride Market Revenue and Volume, by End User

12.1.1. Hospitals

12.1.1.1. Market Revenue and Volume Forecast

12.1.2. Ambulatory Surgical Centers

12.1.2.1. Market Revenue and Volume Forecast

12.1.3. Specialty Weight Loss Clinics

12.1.3.1. Market Revenue and Volume Forecast

12.1.4. Homecare/Telehealth Users

12.1.4.1. Market Revenue and Volume Forecast

Chapter 13. Global Phentermine Hydrochloride Market, By Sales Type

13.1. Phentermine Hydrochloride Market Revenue and Volume, by Sales Type

13.1.1. Branded Drugs

13.1.1.1. Market Revenue and Volume Forecast

13.1.2. Generic Drugs

13.1.2.1. Market Revenue and Volume Forecast

Chapter 14. Global Phentermine Hydrochloride Market, Regional Estimates and Trend Forecast

14.1. North America

14.1.1. Market Revenue and Volume Forecast, by Dosage Form

14.1.2. Market Revenue and Volume Forecast, by Strength

14.1.3. Market Revenue and Volume Forecast, by Route of Administration

14.1.4. Market Revenue and Volume Forecast, by Distribution Channel

14.1.5. Market Revenue and Volume Forecast, by Application

14.1.6. Market Revenue and Volume Forecast, by Sales Type

14.1.7. Market Revenue and Volume Forecast, by End User

14.1.8. U.S.

14.1.8.1. Market Revenue and Volume Forecast, by Dosage Form

14.1.8.2. Market Revenue and Volume Forecast, by Strength

14.1.8.3. Market Revenue and Volume Forecast, by Route of Administration

14.1.8.4. Market Revenue and Volume Forecast, by Distribution Channel

14.1.8.5. Market Revenue and Volume Forecast, by Application

14.1.8.6. Market Revenue and Volume Forecast, by Sales Type

14.1.8.7. Market Revenue and Volume Forecast, by End User

14.1.9. Rest of North America

14.1.9.1. Market Revenue and Volume Forecast, by Dosage Form

14.1.9.2. Market Revenue and Volume Forecast, by Strength

14.1.9.3. Market Revenue and Volume Forecast, by Route of Administration

14.1.9.4. Market Revenue and Volume Forecast, by Distribution Channel

14.1.9.5. Market Revenue and Volume Forecast, by Application

14.1.9.6. Market Revenue and Volume Forecast, by Sales Type

14.1.9.7. Market Revenue and Volume Forecast, by End User

14.2. Europe

14.2.1. Market Revenue and Volume Forecast, by Dosage Form

14.2.2. Market Revenue and Volume Forecast, by Strength

14.2.3. Market Revenue and Volume Forecast, by Route of Administration

14.2.4. Market Revenue and Volume Forecast, by Distribution Channel

14.2.5. Market Revenue and Volume Forecast, by Application

14.2.6. Market Revenue and Volume Forecast, by Sales Type

14.2.7. Market Revenue and Volume Forecast, by End User

14.2.8. UK

14.2.8.1. Market Revenue and Volume Forecast, by Dosage Form

14.2.8.2. Market Revenue and Volume Forecast, by Strength

14.2.8.3. Market Revenue and Volume Forecast, by Route of Administration

14.2.8.4. Market Revenue and Volume Forecast, by Distribution Channel

14.2.8.5. Market Revenue and Volume Forecast, by Application

14.2.8.6. Market Revenue and Volume Forecast, by Sales Type

14.2.8.7. Market Revenue and Volume Forecast, by End User

14.2.9. Germany

14.2.9.1. Market Revenue and Volume Forecast, by Dosage Form

14.2.9.2. Market Revenue and Volume Forecast, by Strength

14.2.9.3. Market Revenue and Volume Forecast, by Route of Administration

14.2.9.4. Market Revenue and Volume Forecast, by Distribution Channel

14.2.9.5. Market Revenue and Volume Forecast, by Application

14.2.9.6. Market Revenue and Volume Forecast, by Sales Type

14.2.9.7. Market Revenue and Volume Forecast, by End User

14.2.10. France

14.2.10.1. Market Revenue and Volume Forecast, by Dosage Form

14.2.10.2. Market Revenue and Volume Forecast, by Strength

14.2.10.3. Market Revenue and Volume Forecast, by Route of Administration

14.2.10.4. Market Revenue and Volume Forecast, by Distribution Channel

14.2.10.5. Market Revenue and Volume Forecast, by Application

14.2.10.6. Market Revenue and Volume Forecast, by Sales Type

14.2.10.7. Market Revenue and Volume Forecast, by End User

14.2.11. Rest of Europe

14.2.11.1. Market Revenue and Volume Forecast, by Dosage Form

14.2.11.2. Market Revenue and Volume Forecast, by Strength

14.2.11.3. Market Revenue and Volume Forecast, by Route of Administration

14.2.11.4. Market Revenue and Volume Forecast, by Distribution Channel

14.2.11.5. Market Revenue and Volume Forecast, by Application

14.2.11.6. Market Revenue and Volume Forecast, by Sales Type

14.2.11.7. Market Revenue and Volume Forecast, by End User

14.3. APAC

14.3.1. Market Revenue and Volume Forecast, by Dosage Form

14.3.2. Market Revenue and Volume Forecast, by Strength

14.3.3. Market Revenue and Volume Forecast, by Route of Administration

14.3.4. Market Revenue and Volume Forecast, by Distribution Channel

14.3.5. Market Revenue and Volume Forecast, by Application

14.3.6. Market Revenue and Volume Forecast, by Sales Type

14.3.7. Market Revenue and Volume Forecast, by End User

14.3.8. India

14.3.8.1. Market Revenue and Volume Forecast, by Dosage Form

14.3.8.2. Market Revenue and Volume Forecast, by Strength

14.3.8.3. Market Revenue and Volume Forecast, by Route of Administration

14.3.8.4. Market Revenue and Volume Forecast, by Distribution Channel

14.3.8.5. Market Revenue and Volume Forecast, by Application

14.3.8.6. Market Revenue and Volume Forecast, by Sales Type

14.3.8.7. Market Revenue and Volume Forecast, by End User

14.3.9. China

14.3.9.1. Market Revenue and Volume Forecast, by Dosage Form

14.3.9.2. Market Revenue and Volume Forecast, by Strength

14.3.9.3. Market Revenue and Volume Forecast, by Route of Administration

14.3.9.4. Market Revenue and Volume Forecast, by Distribution Channel

14.3.9.5. Market Revenue and Volume Forecast, by Application

14.3.9.6. Market Revenue and Volume Forecast, by Sales Type

14.3.9.7. Market Revenue and Volume Forecast, by End User

14.3.10. Japan

14.3.10.1. Market Revenue and Volume Forecast, by Dosage Form

14.3.10.2. Market Revenue and Volume Forecast, by Strength

14.3.10.3. Market Revenue and Volume Forecast, by Route of Administration

14.3.10.4. Market Revenue and Volume Forecast, by Distribution Channel

14.3.10.5. Market Revenue and Volume Forecast, by Application

14.3.10.6. Market Revenue and Volume Forecast, by Sales Type

14.3.10.7. Market Revenue and Volume Forecast, by End User

14.3.11. Rest of APAC

14.3.11.1. Market Revenue and Volume Forecast, by Dosage Form

14.3.11.2. Market Revenue and Volume Forecast, by Strength

14.3.11.3. Market Revenue and Volume Forecast, by Route of Administration

14.3.11.4. Market Revenue and Volume Forecast, by Distribution Channel

14.3.11.5. Market Revenue and Volume Forecast, by Application

14.3.11.6. Market Revenue and Volume Forecast, by Sales Type

14.3.11.7. Market Revenue and Volume Forecast, by End User

14.4. MEA

14.4.1. Market Revenue and Volume Forecast, by Dosage Form

14.4.2. Market Revenue and Volume Forecast, by Strength

14.4.3. Market Revenue and Volume Forecast, by Route of Administration

14.4.4. Market Revenue and Volume Forecast, by Distribution Channel

14.4.5. Market Revenue and Volume Forecast, by Application

14.4.6. Market Revenue and Volume Forecast, by Sales Type

14.4.7. Market Revenue and Volume Forecast, by End User

14.4.8. GCC

14.4.8.1. Market Revenue and Volume Forecast, by Dosage Form

14.4.8.2. Market Revenue and Volume Forecast, by Strength

14.4.8.3. Market Revenue and Volume Forecast, by Route of Administration

14.4.8.4. Market Revenue and Volume Forecast, by Distribution Channel

14.4.8.5. Market Revenue and Volume Forecast, by Application

14.4.8.6. Market Revenue and Volume Forecast, by Sales Type

14.4.8.7. Market Revenue and Volume Forecast, by End User

14.4.9. North Africa

14.4.9.1. Market Revenue and Volume Forecast, by Dosage Form

14.4.9.2. Market Revenue and Volume Forecast, by Strength

14.4.9.3. Market Revenue and Volume Forecast, by Route of Administration

14.4.9.4. Market Revenue and Volume Forecast, by Distribution Channel

14.4.9.5. Market Revenue and Volume Forecast, by Application

14.4.9.6. Market Revenue and Volume Forecast, by Sales Type

14.4.9.7. Market Revenue and Volume Forecast, by End User

14.4.10. South Africa

14.4.10.1. Market Revenue and Volume Forecast, by Dosage Form

14.4.10.2. Market Revenue and Volume Forecast, by Strength

14.4.10.3. Market Revenue and Volume Forecast, by Route of Administration

14.4.10.4. Market Revenue and Volume Forecast, by Distribution Channel

14.4.10.5. Market Revenue and Volume Forecast, by Application

14.4.10.6. Market Revenue and Volume Forecast, by Sales Type

14.4.10.7. Market Revenue and Volume Forecast, by End User

14.4.11. Rest of MEA

14.4.11.1. Market Revenue and Volume Forecast, by Dosage Form

14.4.11.2. Market Revenue and Volume Forecast, by Strength

14.4.11.3. Market Revenue and Volume Forecast, by Route of Administration

14.4.11.4. Market Revenue and Volume Forecast, by Distribution Channel

14.4.11.5. Market Revenue and Volume Forecast, by Application

14.4.11.6. Market Revenue and Volume Forecast, by Sales Type

14.4.11.7. Market Revenue and Volume Forecast, by End User

14.5. Latin America

14.5.1. Market Revenue and Volume Forecast, by Dosage Form

14.5.2. Market Revenue and Volume Forecast, by Strength

14.5.3. Market Revenue and Volume Forecast, by Route of Administration

14.5.4. Market Revenue and Volume Forecast, by Distribution Channel

14.5.5. Market Revenue and Volume Forecast, by Application

14.5.6. Market Revenue and Volume Forecast, by Sales Type

14.5.7. Market Revenue and Volume Forecast, by End User

14.5.8. Brazil

14.5.8.1. Market Revenue and Volume Forecast, by Dosage Form

14.5.8.2. Market Revenue and Volume Forecast, by Strength

14.5.8.3. Market Revenue and Volume Forecast, by Route of Administration

14.5.8.4. Market Revenue and Volume Forecast, by Distribution Channel

14.5.8.5. Market Revenue and Volume Forecast, by Application

14.5.8.6. Market Revenue and Volume Forecast, by Sales Type

14.5.8.7. Market Revenue and Volume Forecast, by End User

14.5.9. Rest of LATAM

14.5.9.1. Market Revenue and Volume Forecast, by Dosage Form

14.5.9.2. Market Revenue and Volume Forecast, by Strength

14.5.9.3. Market Revenue and Volume Forecast, by Route of Administration

14.5.9.4. Market Revenue and Volume Forecast, by Distribution Channel

14.5.9.5. Market Revenue and Volume Forecast, by Application

14.5.9.6. Market Revenue and Volume Forecast, by Sales Type

14.5.9.7. Market Revenue and Volume Forecast, by End User

Chapter 15. Company Profiles

15.1. KVK Tech, Inc.

15.1.1. Company Overview

15.1.2. Product Offerings

15.1.3. Financial Performance

15.1.4. Recent Initiatives

15.2. Teva Pharmaceutical Industries Ltd.

15.2.1. Company Overview

15.2.2. Product Offerings

15.2.3. Financial Performance

15.2.4. Recent Initiatives

15.3. Lannett Company, Inc.

15.3.1. Company Overview

15.3.2. Product Offerings

15.3.3. Financial Performance

15.3.4. Recent Initiatives

15.4. Vintage Pharmaceuticals, LLC (Acella Pharmaceuticals)

15.4.1. Company Overview

15.4.2. Product Offerings

15.4.3. Financial Performance

15.4.4. Recent Initiatives

15.5. CorePharma LLC

15.5.1. Company Overview

15.5.2. Product Offerings

15.5.3. Financial Performance

15.5.4. Recent Initiatives

15.6. Actavis Pharma, Inc. (Now Teva)

15.6.1. Company Overview

15.6.2. Product Offerings

15.6.3. Financial Performance

15.6.4. Recent Initiatives

15.7. Aytu BioPharma, Inc.

15.7.1. Company Overview

15.7.2. Product Offerings

15.7.3. Financial Performance

15.7.4. Recent Initiatives

15.8. Sandoz (a Novartis division)

15.8.1. Company Overview

15.8.2. Product Offerings

15.8.3. Financial Performance

15.8.4. Recent Initiatives

15.9. Micro Labs Ltd.

15.9.1. Company Overview

15.9.2. Product Offerings

15.9.3. Financial Performance

15.9.4. Recent Initiatives

15.10. Tris Pharma, Inc.

15.10.1. Company Overview

15.10.2. Product Offerings

15.10.3. Financial Performance

15.10.4. Recent Initiatives

Chapter 16. Research Methodology

16.1. Primary Research

16.2. Secondary Research

16.3. Assumptions

Chapter 17. Appendix

17.1. About Us

17.2. Glossary of Terms

For questions or customization requests, please reach out to us at sales@precedenceresearch.com

Frequently Asked Questions

The phentermine hydrochloride market size is expected to increase from USD 567.10 million in 2024 to USD 1,115.57 million by 2034.

The phentermine hydrochloride market is expected to grow at a compound annual growth rate (CAGR) of around 7.00% from 2025 to 2034.

The major players in the phentermine hydrochloride market include KVK Tech, Inc., Teva Pharmaceutical Industries Ltd., Lannett Company, Inc., Vintage Pharmaceuticals, LLC (Acella Pharmaceuticals), CorePharma LLC, Actavis Pharma, Inc. (Now Teva), Aytu BioPharma, Inc., Sandoz (a Novartis division), Micro Labs Ltd., Tris Pharma, Inc., Genpharm Inc., Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Ltd., Hikma Pharmaceuticals PLC, Cipla Ltd., Hetero Drugs Ltd., Mylan N.V. (Now part of Viatris Inc.), Lupin Pharmaceuticals, Glenmark Pharmaceuticals, and Torrent Pharmaceuticals Ltd.

The driving factors of the phentermine hydrochloride market are the rising rates of obesity and the increasing awareness of health risks associated with it.

North America region will lead the global phentermine hydrochloride market during the forecast period 2025 to 2034.